» Articles » PMID: 27457237

Should There Be Concern About Autoimmune Diabetes in Adults? Current Evidence and Controversies

Overview
Journal Curr Diab Rep
Publisher Current Science
Specialty Endocrinology
Date 2016 Jul 27
PMID 27457237
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune diabetes has a heterogeneous phenotype. Although often considered a condition starting in childhood, a substantial proportion of type 1 diabetes presents in adult life. This holds important implications for our understanding of the factors that modify the rate of progression through the disease prodrome to clinical diabetes and for our management of the disease. When autoimmune diabetes develops in adulthood, insulin treatment is often not required at the time of diagnosis, and this autoimmune non-insulin requiring diabetes is generally termed latent autoimmune diabetes in adults (LADA). Patients with LADA are generally leaner, younger at diabetes onset; have a greater reduction in C-peptide; and have a greater likelihood of insulin treatment as compared with patients with type 2 diabetes. The LADA subset of patients with adult-onset autoimmune diabetes has highlighted many shortcomings in the classification of diabetes and invokes the case for more personalized data analysis in line with the move towards precision medicine. Perhaps most importantly, the issues highlight our persistent failure to engage with the heterogeneity within the most common form of autoimmune diabetes, that is adult-onset type 1 diabetes, both insulin-dependent and initially non-insulin requiring (LADA). This review discusses characteristics of autoimmune diabetes and specifically aims to illustrate the heterogeneity of the disease.

Citing Articles

Ketoacidosis and SGLT2 Inhibitors: A Narrative Review.

Morace C, Lorello G, Bellone F, Quartarone C, Ruggeri D, Giandalia A Metabolites. 2024; 14(5).

PMID: 38786741 PMC: 11122992. DOI: 10.3390/metabo14050264.


All-Cause Mortality and Cardiovascular and Microvascular Diseases in Latent Autoimmune Diabetes in Adults.

Wei Y, Herzog K, Ahlqvist E, Andersson T, Nystrom T, Zhan Y Diabetes Care. 2023; 46(10):1857-1865.

PMID: 37635682 PMC: 10516249. DOI: 10.2337/dc23-0739.


Human Leukocyte Antigen (HLA) and Islet Autoantibodies Are Tools to Characterize Type 1 Diabetes in Arab Countries: Emphasis on Kuwait.

Jahromi M, Al-Ozairi E Dis Markers. 2019; 2019:9786078.

PMID: 31827651 PMC: 6886320. DOI: 10.1155/2019/9786078.


Adult-onset type 1 diabetes: Predictors of glycaemic control.

Hesse D, Boysen L, Ridderstrale M Endocrinol Diabetes Metab. 2019; 1(4):e00038.

PMID: 30815566 PMC: 6354813. DOI: 10.1002/edm2.38.


Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study.

Rogers M, Kim C, Banerjee T, Lee J BMC Med. 2017; 15(1):199.

PMID: 29115947 PMC: 5688827. DOI: 10.1186/s12916-017-0958-6.


References
1.
Carlsson A, Sundkvist G, Groop L, Tuomi T . Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab. 2000; 85(1):76-80. DOI: 10.1210/jcem.85.1.6228. View

2.
Zinman B, Kahn S, Haffner S, ONeill M, Heise M, Freed M . Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes. 2004; 53(12):3193-200. DOI: 10.2337/diabetes.53.12.3193. View

3.
Pescovitz M, Greenbaum C, Bundy B, Becker D, Gitelman S, Goland R . B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care. 2013; 37(2):453-9. PMC: 3898764. DOI: 10.2337/dc13-0626. View

4.
Beyan H, Drexhage R, van der Heul Nieuwenhuijsen L, de Wit H, Padmos R, Schloot N . Monocyte gene-expression profiles associated with childhood-onset type 1 diabetes and disease risk: a study of identical twins. Diabetes. 2010; 59(7):1751-5. PMC: 2889775. DOI: 10.2337/db09-1433. View

5.
Andersen C, Bennet L, Nystrom L, Lindblad U, Lindholm E, Groop L . Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia. 2012; 56(2):252-8. DOI: 10.1007/s00125-012-2759-y. View